Is the Administration of Parathyroid Hormone in Inflammatory Rheumatic Diseases with Secondary Osteoporosis a Reasonable Therapeutic Option?

被引：1

作者：

Lange, U. ^{[1
]}

机构：

[1] Univ Giessen, Kerckhoff Klin, D-61231 Bad Nauheim, Germany

来源：

AKTUELLE RHEUMATOLOGIE | 2012年 / 37卷 / 04期

关键词：

inflammatory rheumatic diseases; secondary osteoporosis; parathyroid hormone; BONE-MINERAL DENSITY; KAPPA-B LIGAND; RECEPTOR ACTIVATOR; SERUM-LEVELS; OSTEOPROTEGERIN; ARTHRITIS; METABOLISM; PROTEIN; INTERLEUKIN-6; TERIPARATIDE;

D O I：

10.1055/s-0032-1304304

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Inflammatory rheumatic diseases are often accompanied with secondary osteoporosis. The aetiology of bone loss is due to many factors, a central role is played by the inflammatory activity. Glucocorticoids that are often applied in the therapy regime influence bone metabolism and bone mass in different ways. Whether or not the administration of the osteoanabolic parathormone is a reasonable therapeutic option in inflammatory rheumatic diseases with secondary osteoporosis is discussed in the present overview.

引用

页码：238 / 242

页数：5

共 39 条

[21] Regulation of receptor activator of nuclear factor-κB ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase A pathway in murine bone marrow cultures [J].

Lee, SK ;

Lorenzo, JA .

BONE, 2002, 31 (01) :252-259

[22]

Lehmann G, 2010, ARZNEIMITTELTHERAPIE, V28, P277

[23] Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system [J].

Liu, Xin-Hua ;

Kirschenbaum, Alexander ;

Yao, Shen ;

Levine, Alice C. .

SKELETAL DEVELOPMENT AND REMODELING IN HEALTH, DISEASE, AND AGING, 2006, 1068 :225-233

[24] Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion [J].

Lubberts, E ;

Koenders, MI ;

Oppers-Walgreen, B ;

van den Bersselaar, L ;

Coenen-de Roo, CJJ ;

Joosten, LAB ;

van den Berg, WB .

ARTHRITIS AND RHEUMATISM, 2004, 50 (02) :650-659

[25] Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation [J].

Ma, YFL ;

Cain, RL ;

Halladay, DL ;

Yang, XH ;

Zeng, QQ ;

Miles, RR ;

Chandrasekhar, S ;

Martin, TJ ;

Onyia, JE .

ENDOCRINOLOGY, 2001, 142 (09) :4047-4054

[26] Parathyroid hormone: An anabolic treatment for osteoporosis [J].

Morley, P ;

Whitfield, JF ;

Willick, GE .

CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (08) :671-687

[27]

Neumann E, 2007, Z RHEUMATOL, V66, P286, DOI 10.1007/s00393-007-0182-4

[28] The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis:: New insights from animal models [J].

Neumann, E ;

Steffen, G ;

Müller-Ladner, U .

ARTHRITIS AND RHEUMATISM, 2005, 52 (10) :2960-2967

[29]

NIALL HD, 1974, P NATL ACAD SCI USA, V71, P384, DOI 10.1073/pnas.71.2.384

[30]

Oelzner P, 2007, Z RHEUMATOL, V66, P337, DOI 10.1007/s00393-007-0157-5

← 1 2 3 4 →